{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:53:44Z","timestamp":1787698424789,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012269","name":"Science and Technology Innovative Research Team in Higher Educational Institutions of Hunan Province","doi-asserted-by":"publisher","award":["No. 23K07203"],"award-info":[{"award-number":["No. 23K07203"]}],"id":[{"id":"10.13039\/501100012269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"DOI":"10.1186\/s41824-025-00255-7","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T22:02:38Z","timestamp":1751320958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Myocardium-to-cavity ratio derived from simultaneous 99mTc-PYP\/201Tl dual-isotope SPECT imaging to differentially diagnose transthyretin cardiac amyloidosis"],"prefix":"10.1186","volume":"9","author":[{"given":"Shozo","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7188-8746","authenticated-orcid":false,"given":"Kenichi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"255_CR1","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s00259-016-3467-5","volume":"43","author":"D Agostini","year":"2016","unstructured":"Agostini D, Marie PY, Ben-Haim S, Rouzet F, Songy B, Giordano A et al (2016) Performance of cardiac cadmium-zinc-telluride gamma camera imaging in coronary artery disease: a review from the cardiovascular committee of the European Association of Nuclear Medicine (EANM). Eur J Nucl Med Mol Imaging 43:2423\u20132432","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"255_CR2","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1007\/s12350-023-03214-6","volume":"30","author":"Z Al Taha","year":"2023","unstructured":"Al Taha Z, Alibazoglu D, Sabbour H, Romany I, Alibazoglu H, Bokhari S (2023) Attacking the Achilles heel of cardiac amyloid nuclear scintigraphy: how to reduce equivocal and false positive studies. J Nucl Cardiol 30:1922\u20131934","journal-title":"J Nucl Cardiol"},{"key":"255_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12350-020-02328-5","volume":"28","author":"T Asif","year":"2021","unstructured":"Asif T, Gomez J, Singh V, Doukky R, Nedeltcheva A, Malhotra S (2021) Comparison of planar with tomographic pyrophosphate scintigraphy for transthyretin cardiac amyloidosis: perils and pitfalls. J Nucl Cardiol 28:104\u2013111","journal-title":"J Nucl Cardiol"},{"key":"255_CR4","unstructured":"ASNC cardiac amyloidosis practice points update: 99mTechnetium-pyrophosphate Imaging for transthyretin cardiac amyloidosis.First Issued: February 2016, Version 3.0: updated March 2021. https:\/\/www.asnc.org\/wp-content\/uploads\/2024\/05\/19110-2021-ASNC-Amyloid-Practice-Points-PYP-MAY19-2022-1.pdf"},{"key":"255_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12350-022-02988-5","volume":"30","author":"JC Avalon","year":"2023","unstructured":"Avalon JC, Fuqua J, Deskins S, Miller T, Conte J, Martin D et al (2023) Quantitative single photon emission computed tomography derived standardized uptake values on 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis. J Nucl Cardiol 30:127\u2013139","journal-title":"J Nucl Cardiol"},{"key":"255_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","volume":"6","author":"S Bokhari","year":"2013","unstructured":"Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS (2013) (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 6:195\u2013201","journal-title":"Circ Cardiovasc Imaging"},{"key":"255_CR7","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","volume":"1","author":"A Castano","year":"2016","unstructured":"Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R et al (2016) Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients With ATTR cardiac amyloidosis. JAMA Cardiol 1:880\u2013889","journal-title":"JAMA Cardiol"},{"key":"255_CR8","first-page":"e000029","volume":"14","author":"S Dorbala","year":"2021","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA et al (2021a) ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. Circ Cardiovasc Imaging 14:e000029","journal-title":"Circ Cardiovasc Imaging"},{"key":"255_CR9","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2967\/jnumed.120.247312","volume":"62","author":"S Dorbala","year":"2021","unstructured":"Dorbala S, Park MA, Cuddy S, Singh V, Sullivan K, Kim S et al (2021b) Absolute quantitation of cardiac (99m)Tc-pyrophosphate using cadmium-zinc-telluride-based SPECT\/CT. J Nucl Med 62:716\u2013722","journal-title":"J Nucl Med"},{"key":"255_CR10","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1007\/s12350-023-03379-0","volume":"30","author":"O Hudson","year":"2023","unstructured":"Hudson O, Hage FG (2023) Single photon emission computed tomography pyrophosphate imaging for transthyretin cardiac amyloid. J Nucl Cardiol 30:2615\u20132617","journal-title":"J Nucl Cardiol"},{"key":"255_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s12350-019-01997-1","volume":"28","author":"M Hussain","year":"2021","unstructured":"Hussain M, Collier P, Jaber W (2021) Value of SPECT imaging in patients with TTR-amyloid: ratios are not enough. J Nucl Cardiol 28:747\u2013749","journal-title":"J Nucl Cardiol"},{"key":"255_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40001-023-01629-y","volume":"29","author":"A Imakhanova","year":"2024","unstructured":"Imakhanova A, Ideguchi R, Kawano H, Maemura K, Kudo T (2024) Optimizing cardiac amyloidosis assessment: utility of 1-h and 3-h (99m)Tc-PYP imaging. Eur J Med Res 29:32","journal-title":"Eur J Med Res"},{"key":"255_CR13","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1253\/circj.CJ-20-0110","volume":"84","author":"H Kitaoka","year":"2020","unstructured":"Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T et al (2020) JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J 84:1610\u20131671","journal-title":"Circ J"},{"key":"255_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1071-3581(96)90002-1","volume":"3","author":"T Krause","year":"1996","unstructured":"Krause T, Zeiher A, Kasper W, Schwehn M, Sch\u00fcmichen C, Moser E (1996) Combined thallium 201\/technetium 99m-labeled pyrophosphate tomography for identification of the \u201cculprit\u201d vessel in acute myocardial infarction. J Nucl Cardiol 3:105\u2013113","journal-title":"J Nucl Cardiol"},{"key":"255_CR15","first-page":"10","volume":"27","author":"T Kudo","year":"2024","unstructured":"Kudo T, Kuji I, Nakajima K, Fukushima K, Maruno H, Iguchi N et al (2024) Nuclear medicine imaging for the diagnosis of ATTR cardiac amyloidosis: report of japanese society of nuclear cardiology working group. Sinzokakuigaku [Nuclear Cardiolgoy]. Off J Jpn Soc Nucl Cardiol 27:10\u201313 (in Japanese)","journal-title":"Off J Jpn Soc Nucl Cardiol"},{"key":"255_CR16","doi-asserted-by":"publisher","first-page":"897202","DOI":"10.1155\/2011\/897202","volume":"2011","author":"AM Larkin","year":"2011","unstructured":"Larkin AM, Serulle Y, Wagner S, Noz ME, Friedman K (2011) Quantifying the Increase in radiation exposure associated with SPECT\/CT compared to SPECT alone for routine nuclear medicine examinations. Int J Mol Imaging 2011:897202","journal-title":"Int J Mol Imaging"},{"key":"255_CR17","doi-asserted-by":"publisher","first-page":"e010249","DOI":"10.1161\/CIRCIMAGING.119.010249","volume":"13","author":"A Masri","year":"2020","unstructured":"Masri A, Bukhari S, Ahmad S, Nieves R, Eisele YS, Follansbee W et al (2020) Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging 13:e010249","journal-title":"Circ Cardiovasc Imaging"},{"key":"255_CR18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1161\/CIRCRESAHA.117.310982","volume":"121","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Blauwet LA, Gertz MA (2017) Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 121:819\u2013837","journal-title":"Circ Res"},{"key":"255_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0002-9343(00)00471-X","volume":"109","author":"PS Mueller","year":"2000","unstructured":"Mueller PS, Edwards WD, Gertz MA (2000) Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 109:181\u2013188","journal-title":"Am J Med"},{"key":"255_CR20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s12149-017-1191-2","volume":"31","author":"K Nakajima","year":"2017","unstructured":"Nakajima K, Okuda K, Yokoyama K, Yoneyama T, Tsuji S, Oda H et al (2017) Cross calibration of (123)I-meta-iodobenzylguanidine heart-to-mediastinum ratio with D-SPECT planogram and Anger camera. Ann Nucl Med 31:605\u2013615","journal-title":"Ann Nucl Med"},{"key":"255_CR21","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.amjmed.2005.06.017","volume":"118","author":"MA Neben-Wittich","year":"2005","unstructured":"Neben-Wittich MA, Wittich CM, Mueller PS, Larson DR, Gertz MA, Edwards WD (2005) Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J Med 118:1287","journal-title":"Am J Med"},{"key":"255_CR22","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s12350-022-03133-y","volume":"30","author":"KJ Nichols","year":"2023","unstructured":"Nichols KJ, Yoon SY, Van Tosh A, Palestro CJ (2023) (99m)Tc-PYP SPECT and SPECT\/CT quantitation for diagnosing cardiac transthyretin amyloidosis. J Nucl Cardiol 30:1235\u20131245","journal-title":"J Nucl Cardiol"},{"key":"255_CR23","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1007\/s12350-017-0867-2","volume":"24","author":"R Otsuka","year":"2017","unstructured":"Otsuka R, Kubo N, Miyazaki Y, Kawahara M, Takaesu J, Fukuchi K (2017) Current status of stress myocardial perfusion imaging pharmaceuticals and radiation exposure in Japan: results from a nationwide survey. J Nucl Cardiol 24:1850\u20131855","journal-title":"J Nucl Cardiol"},{"key":"255_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1136\/hrt.2005.061911","volume":"92","author":"E Perugini","year":"2006","unstructured":"Perugini E, Rapezzi C, Piva T, Leone O, Bacchi-Reggiani L, Riva L et al (2006) Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 92:343\u2013349","journal-title":"Heart"},{"key":"255_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40658-020-00342-7","volume":"8","author":"C Ren","year":"2021","unstructured":"Ren C, Ren J, Tian Z, Du Y, Hao Z, Zhang Z et al (2021) Assessment of cardiac amyloidosis with (99m)Tc-pyrophosphate (PYP) quantitative SPECT. EJNMMI Phys 8:3","journal-title":"EJNMMI Phys"},{"key":"255_CR26","first-page":"193","volume":"34","author":"RR Roberti","year":"1993","unstructured":"Roberti RR, Van Tosh A, Baruchin MA, Gallagher R, Friedman P, Ventura B, Horowitz SF (1993) Left ventricular cavity-to-myocardial count ratio: a new parameter for detecting resting left ventricular dysfunction directly from tomographic thallium perfusion scintigraphy. J Nucl Med 34:193\u2013198","journal-title":"J Nucl Med"},{"key":"255_CR27","first-page":"766","volume":"38","author":"R Sciagra","year":"1997","unstructured":"Sciagra R, Bisi G, Buonamici P, Zerauschek F, Santoro GM, Meldolesi U, Fazzini PF, Pupi A (1997) Left ventricular cavity-to-myocardium count ratio in technetium-99m-sestamibi SPECT in the detection of patient with left ventricular dysfuntion. J Nucl Med 38:766\u2013770","journal-title":"J Nucl Med"},{"key":"255_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12350-018-01552-4","volume":"26","author":"V Singh","year":"2019","unstructured":"Singh V, Falk R, Di Carli MF, Kijewski M, Rapezzi C, Dorbala S (2019) State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol 26:158\u2013173","journal-title":"J Nucl Cardiol"},{"key":"255_CR29","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.6009\/jjrt.2022-1297","volume":"78","author":"K Takata","year":"2022","unstructured":"Takata K, Shibutani N, Horita H (2022) Utility of the method for calculating the heart to contralateral ratio for cardiac amyloidosis by using ray-summation images in (99m)Tc-pyrophosphate scintigraphy. Nihon Hoshasen Gijutsu Gakkai Zasshi 78:1399\u20131405","journal-title":"Nihon Hoshasen Gijutsu Gakkai Zasshi"},{"key":"255_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12350-019-01753-5","volume":"27","author":"B Tamarappoo","year":"2020","unstructured":"Tamarappoo B, Otaki Y, Manabe O, Hyun M, Cantu S, Arnson Y et al (2020) Simultaneous Tc-99m PYP\/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis. J Nucl Cardiol 27:28\u201337","journal-title":"J Nucl Cardiol"},{"key":"255_CR31","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1007\/s12350-021-02857-7","volume":"29","author":"S Watanabe","year":"2022","unstructured":"Watanabe S, Nakajima K, Wakabayashi H, Yoneyama H, Yoshida S, Komatsu J et al (2022) Volumetric evaluation of (99m)Tc-pyrophosphate SPECT\/CT for transthyretin cardiac amyloidosis: methodology and correlation with cardiac functional parameters. J Nucl Cardiol 29:3102\u20133110","journal-title":"J Nucl Cardiol"},{"key":"255_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ (1950) Index for rating diagnostic tests. Cancer 3:32\u201335","journal-title":"Cancer"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-025-00255-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-025-00255-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-025-00255-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T22:02:40Z","timestamp":1751320960000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhi.springeropen.com\/articles\/10.1186\/s41824-025-00255-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["255"],"URL":"https:\/\/doi.org\/10.1186\/s41824-025-00255-7","relation":{},"ISSN":["3005-074X"],"issn-type":[{"value":"3005-074X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board at the Public Central Hospital of Matto Ishikawa approved this retrospective study of innominate patients (Approval ID: R5-21). The Board waived the need for written informed consent because 99mTc-PYP\/201Tl assessments were routinely included in clinical practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for the use of data for scientific research and publication was obtained for all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K. Nakajima has collaborative research with PDRadiopharma, Inc. Tokyo, Japan, and Spectrum Dynamics Medical, Caesarea, Israel. Other coauthors declare nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}